Micro-infusion system developer Mercator MedSystems has received $11m in a round led by Salubris, which has licensed its technology in China.
Pharmaceutical company Shenzhen Salubris Pharmaceuticals has led an $11m series D round for US-based catheter technology developer Mercator MedSystems that included unnamed new and existing investors.
Mercator develops catheter-based micro-infusion systems that can infuse drugs or biologics through veins or arteries, and the technology is generally used for cardiovascular and pulmonary disease.
Salubris invested after obtaining the clinical development and manufacturing rights for Mercator’s Bullfrog Device in China through a deal that will make Mercator eligible for milestone payments.
Mercator…
